(0.05%) 5 472.06 points
(0.09%) 39 149 points
(0.33%) 17 775 points
(-0.24%) $80.64
(-3.66%) $2.66
(-0.79%) $2 312.40
(0.15%) $28.91
(3.51%) $1 021.00
(0.29%) $0.936
(0.68%) $10.68
(0.45%) $0.792
(-0.28%) $87.25
Live Chart Being Loaded With Signals
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing for various genetic disorders...
Stats | |
---|---|
今日成交量 | 401 467 |
平均成交量 | 29 535 |
市值 | 3.02M |
EPS | $1.030 ( Q1 | 2024-05-09 ) |
下一个收益日期 | ( $0 ) 2024-08-12 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.0266 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.122 (0.74%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-25 | Alloway Paul | Buy | 23 530 | Common Stock |
2024-03-25 | Alloway Paul | Sell | 18 090 | Restricted Stock Units |
2024-03-25 | Michaud Charles Jr | Buy | 6 448 | Common Stock |
2024-03-25 | Michaud Charles Jr | Sell | 5 360 | Restricted Stock Units |
2024-01-01 | Tzianabos Arthur | Buy | 19 140 | Common Stock |
INSIDER POWER |
---|
34.05 |
Last 94 transactions |
Buy: 1 681 707 | Sell: 632 243 |
Homology Medicines Inc 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Homology Medicines Inc 相关性 - 货币/商品
Homology Medicines Inc 财务报表
Annual | 2023 |
营收: | $1.16M |
毛利润: | $578 000 (50.00 %) |
EPS: | $-351.57 |
FY | 2023 |
营收: | $1.16M |
毛利润: | $578 000 (50.00 %) |
EPS: | $-351.57 |
FY | 2022 |
营收: | $3.21M |
毛利润: | $609 000 (18.98 %) |
EPS: | $0.00840 |
FY | 2021 |
营收: | $33.97M |
毛利润: | $0.00 (0.00 %) |
EPS: | $-1.901 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Homology Medicines Inc
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing for various genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, cardiac and skeletal muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II, as well as HMI-104 for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。